December 2021 - Page 18 of 28

FridayDec 10, 2021 9:31 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) New Patent Application Offering Improved Delivery Control, Enhanced Shelf Stability, of Psilocin

The full patent application covers multiple families of psilocin analogs. Psilocin is the active metabolite of psilocybin In addition to improving delivery control, the company’s dermal application route can potentially eliminate undesirable side effects such as nausea Mydecine appoints Dr. Saeid Babaei, PhD, as an independent board member. The appointment can help advance the company’s NASDAQ listing efforts, bringing decades of experience in biotech development and licensing and strategic advancements Company intends to uplist to NASDAQ in Q1 2022 Improving delivery control and shelf stabilization of psilocybin’s active metabolite psilocin, two critical aspects for use in medical settings, is the…

ThursdayDec 09, 2021 2:43 pm

QualityStocksNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Financing to Provide Runway for Key Milestones

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced its entry into an agreement with an investor to complete a non-brokered private placement (the “financing”) of a convertible secured subordinated debenture in the principal amount of C$5.5 million. According to the update, the financing is expected to close on Dec. 10, 2021. “I would like to thank our incredible strategic shareholder for stepping up in a tough, volatile market and continuing to support and expand upon your large stake in Mydecine,” said the…

ThursdayDec 09, 2021 2:27 pm

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Study Marks First Phase 2 Trial to Evaluate Cannabinol as Therapeutic Option for Disease Treatment

InMed Pharmaceuticals (NASDAQ: INM) recently released its Q1 2022 financial results along with a business update showing positive momentum across all of its programs. Following the acquisition of BayMedica Inc. in October that created an industry leader in the manufacture and commercialization of rare cannabinoids, management expects to introduce multiple new, rare cannabinoids in the near future, focusing on high demand, attractive margin products. In late September, InMed commenced the 755-201-EB study, its phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders scientifically known as Epidermolysis Bullosa (“EB”). A recent article…

ThursdayDec 09, 2021 2:15 pm

FingerMotion Inc. (FNGR) Research Agreement with Munich Re Sets Stage for Predictive Insurance Analysis Growth

Rich communication services (“RCS”) provider and big data analysis solutions developer FingerMotion has announced an agreement with Munich Re to form a collaborative research alliance to benefit life and health insurance risk evaluation FingerMotion focuses its SMS, MMS, and big data products on China’s huge high-end phone consumer market The company’s most recent quarterly report noted a 25 percent YOY quarterly growth in revenues attributed to SMS and MMS services The Munich Re agreement follows FingerMotion’s contract earlier this year with Pacific Life Reinsurance to provide big data analytical services for Pacific Life’s insurance operations in China Communications and big…

ThursdayDec 09, 2021 1:59 pm

QualityStocksNewsBreaks – DigiMax Global Inc.’s (CSE: DIGI) (OTC: DBKSF) AI Solution Helping Employers Identify Right Talent, Users Identify Personality Traits

DigiMax Global (CSE: DIGI) (OTC: DBKSF), a company that provides artificial intelligence (“AI”) and cryptocurrency technology solutions, is poised to benefit from the fact that AI technology may just be what companies need to make decisions on hiring the right talent and personality for a job. DIGI’s Projected Personality Interpreter (“PPI”), which was originally conceived and launched by Darwin Ecosystems, a company that was acquired by DigiMax late last year, evaluates a company’s workforce, brand and culture by revealing the personality traits and sentiments buried in human expression. “By leveraging IBM Watson and a customer algorithm that analyzes applicant responses across…

ThursdayDec 09, 2021 1:54 pm

Flora Growth Corp. (NASDAQ: FLGC) Launches European and Mexican Exports of CBD Skincare Brands

Colombian cannabis cultivator and international wellness product builder Flora Growth Corp. is building a global pipeline for its wide array of branded CBD and medicinal cannabis products The company recently announced that it has begun fulfilling the first orders for its Mind Naturals and Awe CBD skincare brands with exports to Spain and Mexico outlets this month Flora Growth cultivates cannabis at its 100-hectare (247-acre) property in central Colombia Flora also has a GMP certified 16,000-square-foot manufacturing facility in Bogota that produces nearly 200 products for the CBD derivatives and medical cannabis markets Cannabis cultivator and worldwide cannabidiol (“CBD”) brand…

ThursdayDec 09, 2021 1:34 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Proceed with its Phase 2a Fibromyalgia Study Following FDA Confirmation

Tryp just announced FDA confirmation for its IND application filed in November 2021 The confirmation allows the company to proceed with its Phase 2a study on the effectiveness of psilocybin-assisted therapy among patients with fibromyalgia This clinical study will be one of the first to evaluate synthetic psilocybin for fibromyalgia in a Phase 2 study It is set to commence in 2022 and will involve 20 fibromyalgia patients Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced that it would be proceeding with its upcoming Phase 2a fibromyalgia study, following a confirmation from the U.S. Food and Drug Administration (“FDA”) (https://ibn.fm/C20cT).…

ThursdayDec 09, 2021 1:24 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Fund, Support First-Ever Psychedelic Treatment Clinic at Manhattan Hospital

Company receives grant to fund clinic for marginalized, underserved NYC communities New clinic will offer psychedelic treatment with no out-of-pocket cost for individuals unable to afford the service Program’s clinicians will receive specialized training Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is marking key milestones in its mission to revolutionize mental healthcare. The company recently received a grant for the first-ever psychedelic treatment clinic at Lenox Hill Hospital (https://ibn.fm/zyerA). Part of Northwell Health, the largest healthcare system in New York State, Lenox Hill Hospital serves marginalized and underserved communities on the Upper East…

ThursdayDec 09, 2021 12:56 pm

QualityStocksNewsBreaks – Avricore Health Inc.’s (TSX.V: AVCR) (OTCQB: AVCRF) Milestones Highlight HealthTab’s Endless Diagnostic Possibilities

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) has, since the company’s inception, been driven by the development of a network of point-of-care (“POC”) analyzers that run on its HealthTab(TM) software in community pharmacies, workplaces and rural areas. Earlier this year, the company signed a deal with Abbott to expand the distribution of its Affinion 2 analyzers in pharmacies. Shortly thereafter, Avricore also entered an agreement with Shoppers Drug Mart to stock HealthTab for diabetes screening in 11 different locations. “The company has recognized an opportunity and capitalizes on established consumer trends, technology advancements, health policy and industry changes to solve a…

ThursdayDec 09, 2021 12:16 pm

QualityStocksNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces January 2022 Conference Participation Schedule

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced details regarding Matt Stang, co-founder and CEO of Delic, and his participation at upcoming January events. According to the update, he will present on the company’s expansion strategy and industry outlook heading into the new year and offer one-on-one meetings with investors at the HC Wainwright Bioconnect Conference. The virtual event is slated to take place Jan. 10-13, 2022, and feature numerous presenting companies, fireside discussions and meetings with H.C. Wainwright investment banking and research teams. In addition, Stang will…

Site Search

Company Search

Month: December 2021